Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 8, Issue 3, Pages 329-350Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656566.8.3.329
Keywords
antibiotic resistance; dosing; Helicobacter pylori; pharmacokinetics
Categories
Ask authors/readers for more resources
Helicobacter pylori infection is a major cause of diseases located in the upper gastrointestinal tract. Successful eradication of the bacteria may improve H. pylori-related symptomatic complaints in functional dyspepsia, cure peptic ulcer disease and prevent gastric cancer. As vaccines are not available, the search for the optimal drug regimen has dominated the last decade. Today, most countries prefer a 7- to 10-day regimen containing a proton pump inhibitor, clarithromycin and amoxicillin as first-line treatment. An alternative (or second-line) treatment contains a proton pump inhibitor, bismuth, tetracycline and metronidazole. This review also highlights the impact of new drugs, new drug combinations, and their optimal dosing required to maximise clinical outcome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available